
President Joe Biden is expected to sign an executive order aimed at lowering drug prices; the FDA imposes limits on who should receive a controversial new Alzheimer disease drug; western US states prepare for a second heat wave.
President Joe Biden is expected to sign an executive order aimed at lowering drug prices; the FDA imposes limits on who should receive a controversial new Alzheimer disease drug; western US states prepare for a second heat wave.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Moderna starts testing for its new mRNA seasonal flu vaccine; the worldwide COVID-19 death toll hits 4 million as Delta variant spreads; more states sign on to Purdue Pharma's bankruptcy reorganization plans after additional payments and release of documents are added to the deal.
Here are some of the latest developments in multiple sclerosis (MS) from our sister publication, NeurologyLive®.
Meena Seshamani, MD, PhD, is named deputy administrator and director of Center for Medicare; United States falls short of President Joe Biden’s Independence Day vaccination goal, with large variation between state vaccination rates; study finds those who smoke menthol cigarettes have more trouble quitting than those who smoke unflavored cigarettes.
Ambulance response services in rural communities face increasing recruitment and expense burdens; data from Israel show a decline in Pfizer/BioNTech COVID-19 vaccine efficacy in preventing symptomatic SARS-CoV-2 infection; the US Supreme Court will hear a case on 340B drug payment cuts.
An overview of the latest news in Parkinson disease reported across MJH Life Sciences™.
A heat wave affecting the Pacific Northwest region of the United States and parts of Canada is linked with hundreds of deaths; Arkansas sees a rise in COVID-19 cases; updates to federal funeral assistance program.
Vaccination rates among Medicaid beneficiaries remain low; Walmart introduces a less expensive insulin option; Moderna says its vaccine is effective against the delta variant.
House of Representatives passes 2 pieces of legislation to boost funding in scientific research; Juul agrees to pay $40 million settlement to North Carolina for its role in the teen vaping epidemic; LA County Department of Public Health recommends for all residents to wear masks in public indoor places amid Delta variant concerns.
Health experts call for the FDA to move faster in fully approving COVID-19 vaccines to combat hesitancy; long-term effects of COVID-19 may impact risk of complications when undergoing elective surgeries; Johnson & Johnson (J&J) agrees to a $230 million opioid settlement with the state of New York.
An overview of the latest news in Parkinson disease (PD) reported across MJH Life Sciences™.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Study highlights variability in COVID-19 testing among LGBTQ+ populations; most COVID-19 deaths are among unvaccinated individuals; FDA grants emergency use authorization (EUA) for Roche drug.
The average US life expectancy decreased by nearly 2 years from 2018 to 2020, with minority groups affected the most; the FDA will add a rare heart inflammation warning to fact sheets for the Pfizer and Moderna COVID-19 vaccines; a series of expansions to the Medicaid safety-net program is reportedly in consideration.
Highlighting the latest ophthalmology-related news reported across MJH Life Sciences™.
Blue Cross Blue Shield aims to fight increasing drug prices with a new pharmacy solutions company; Anthony Fauci, MD, warns about the growing threat from the Delta variant; COVID-19–related death rates highest in Texas border counties.
The Biden administration shifts its planned vaccine donation from 80 million to 55 million vaccines amid ongoing safety review of AstraZeneca doses; a CMS report indicates that nearly 10 million individuals enrolled in Medicaid and CHIP amid the pandemic; significantly more deaths by suicide are reported than combat deaths in the US military.
The national supply of blood is dropping to dangerously low levels nationwide; the Veterans Health Administration will offer gender-affirming surgeries to transgender veterans; several vulnerable states are spotlighted amid the spread of the more transmissible delta COVID-19 variant.
An overview of the latest news in Parkinson disease reported across MJH Life Sciences™.
The latest happenings in the heart failure space from across MJH Life Sciences™.
Highlighting the latest ophthalmology-related news reported across MJH Life Sciences™.
The Biden administration has promised to invest billions in antiviral medicine development; certain hospitals associated with Black patients' COVID-19 mortality rates; increased rates of medicaid enrollment.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Here are some of the latest developments in multiple sclerosis (MS) from our sister publication, NeurologyLive®.
The effectiveness of CureVac's COVID-19 vaccine is among the lowest reported; a new report highlights kickbacks and medical industry payments from device makers to surgeons; Australia limits use of AstraZeneca's COVID-19 vaccine to people over 60 years.
The CDC classifies the COVID-19 Delta variant a “variant of concern”; results from Regeneron Pharmaceuticals show positive survival benefits in antibody-naïve patients hospitalized because of COVID-19; sexually transmitted diseases (STDs) reach new record levels in the United States.
The debate continues whether or not to go maskless when fully vaccinated; the Delta COVID-19 variant is associated with a 2-fold greater risk of hospitalization; an extra vaccine dose may boost COVID-19 protection in organ transplant recipients.
Novavax releases positive phase 3 trial data on its COVID-19 vaccine candidate; data show sharp increase in emergency department visits for attempted suicide; decrease in pediatric inpatient units throughout the country.
High-risk patients with diffuse large B-cell lymphoma (DLBCL) may benefit from being treated with a regimen that adds zanubrutinib and lenalidomide to R-CHOP (a combination of the monoclonal antibody rituximab plus the chemotherapy regimen of cyclophosphamide, doxorubicin, vincristine, and prednisone).
259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.